Introduction
The history of clinical research has evolved over centuries, between continents, and among disciplines into the modern era of clinical trials. The first recorded trial can be found in biblical writings between 605 and 562 BC. Records document an official order by King Nebuchadnezzar, a military leader in Babylon, that instructs people to eat a diet of meat and wine only, which he believed would keep them physically fit and healthy (Collier, 2009 ). However, a group of young men rebelled against the order and the king allowed them to consume vegetables and water instead. After 10 days, those with the vegetarian diet appeared better nourished than those who consumed the meat and wine diet (Collier, 2009) . Despite its simplicity, this record of the first trial shows how experimentation has guided decisions, which in turn has had a broader impact on the overall public health (Bhatt, 2010; Collier, 2009) .
Dr. James Lind is often credited with conducting the first clinical trial in modern times (Bhatt, 2010; Collier, 2009) . Although the study was not perfect, he implemented the first control group within his study and found that adding citrus fruit to the diets of sailors could prevent scurvy (Bartholomew, 2002) . By 1863, another element of modern clinical trial protocols, the placebo, was added to research studies (de Craen et al., 1999) . In the1900s, more advanced concepts such as randomization and treatment blinding were introduced and utilized in research studies (Bhatt, 2010) .
As the nature of clinical trials evolved, the protection of human study subjects also increased. Before the 20th century, ethical principles for the care of patients were rooted in the ancient Hippocratic Oath but not strictly adhered to and efforts to protect human subjects from harm or mistreatment were often reactionary rather than anticipatory. This issue was addressed with the creation of the Nuremberg Code and The Declaration of Helsinki, which outlined global rules of conduct for human experimentation. The United States also implemented its own laws and regulatory organizations to govern clinical trial research; however, many years, legislative acts, and unfortunate deaths passed before the U.S. Food and Drug Administration (FDA) in its current form was established to strictly regulate all stages of drug development, manufacturing, and marketing (Borchers et al., 2007) .
Today, clinical trials are the backbone of contemporary medicine. Randomized, double-blinded, placebo-controlled clinical studies are critical for the advancement of medicine and the field of dermatology.
Since 2011, eight new therapies have been approved by the FDA for the treatment of patients with metastatic melanoma, including four immunotherapy agents and four targeted therapies. Since the early 2000s, targeted immunotherapy for patients with psoriasis has become a strong focus in clinical research and resulted in the development of new therapeutics on a yearly basis and half a dozen agents that are currently under development.
Skin conditions are among the most common health problems in the United States and one in three people are affected at any given time, which is more common than obesity, cancer, and hypertension (Bickers et al., 2006) . Dermatologic diseases increase both direct and indirect medical costs and present a challenge to the quality of life of affected patients. In addition to the clinical presentation, skin conditions can also manifest as severe pruritus and cause impaired movement and debilitating emotional effects (Bickers et al., 2006) . Psoriasis, for example, is an autoimmune skin disorder that severely impacts health-related quality of life (Rapp et al., 1999) and patients report reduced physical and mental functioning that is comparable with that of patients with cancer, arthritis, hypertension, heart disease, diabetes, and depression. Measures of treatment efficacy within clinical trials should not only focus on clinical improvement but also incorporate patients' perceptions of quality of life improvement to more holistically treat the psychosocial aspects of dermatological diseases (Charman et al., 2003) .
The clinical trials unit
To maximize safety and efficacy, clinical trials are conducted in four separate phases. Phase I trials are initial tests on a small group of human subjects to determine treatment safety, dose range, and potential side effects (Collier, 2009) . Phase II trials are conducted on a larger group of people to determine treatment efficacy (Sedgwick, 2014) . Phase III trials involve the randomized and controlled multicenter study of even larger populations to determine and confirm the effectiveness of the treatment or drug in question (Sedgwick, 2014) . Lastly, Phase IV studies typically occur after marketing of the product and assess the long-term adverse events and effects in varying populations (Collier, 2009) .
Clinical trials can be conducted at academic medical centers and in private practice settings. Typically, the study sponsor is a pharmaceutical company that studies a drug, treatment, or device with the goal of marketing the product to the public. The pharmaceutical industry has financially sponsored and supported approximately twothird of all clinical trials in the United States between 2008 and 2013. This estimate is even higher for studies that were conducted in the field of dermatology (Campa et al., 2016) .
Every study team includes a clinician who serves as the principal investigator (PI) who is responsible for the study conduct and oversight of the research activities. First, the PI is approached by a pharmaceutical company to determine the PI's interest in conducting the research and generate an initial contract. Next, the PI signs a confidentiality agreement to assure nondisclosure of any proprietary information that is related to the research. The sponsor of the study will then assess, through a questionnaire and communication with the PI, whether the trial can be conducted at the PI's site. The questionnaire surveys the investigator's experience, information on the site and patient population, and provides the PI with the full study protocol to determine whether the physician can feasibly conduct the study with use of the facility, available resources, and support staff. After this information is collected, sponsor representatives conduct a preliminary onsite visit to confirm that the site is adequate to support a trial, including an onsite review of space for storage of study records and study drug and the study protocol with personnel who are involved in the trial. After selection of the trial site, multiple PIs and coordinators convene during an investigators' meeting to discuss details of the protocol and exchange information about the study (Carson, 2006) . It is also important for the PI to be aware of the hypothesis or question under evaluation and whether it aligns with what Bagatin and Miot (2013) refer to as the feasible, interesting, novel, ethical, and relevant (FINER) criteria.
The next critical step before initiation of the study is approval by an institutional review board (IRB). The study site must submit documents with regard to the study protocol, patient informed consent, drug and/or treatment to be studied, and other relevant details to protect the subjects who will be recruited for the study. IRB approval can present a challenge to research sites that initiate studies because it can significantly delay the start of a trial. Check et al. (2013) reviewed literature in support of a centralized IRB approval process instead of the common local IRB approval process and found that there are proponents of both procedures. Proponents of the centralized IRB review value consistency among sites and those who prefer the local review process raise concerns about the loss of quality of the review and of the emphasis on the context of the local community (Check et al., 2013) .
Informed consent documents are also critical to initiate a study and provide study subjects with the information they need to make a well-informed decision about participation in the trial. Once the IRB approval process is satisfactorily completed, the PI will submit multiple regulatory documents and a clinical trial agreement to indicate the sponsor's responsibility to fund the trial. The site initiation visit is the final step before subjects can be enrolled in the study. Study representatives at the site will receive all the necessary equipment and documents from the sponsor and meet with the clinical research associate who will monitor the study throughout the course of the trial. Once a site is fully approved and initiated, enrollment of subjects can begin (Carson, 2006) .
For all trials, one main concern of investigators is subject recruitment, especially at sites that do not have an adequate patient population for the study in question. Some academic centers rely on a patient registry or database to find potential study subjects (Bain, 2005) whereas others use broadcast messaging techniques, flyers, letters, phone calls, and presentations to health care providers (Aitken et al., 2008) . Recruitment is crucial to the success of the study because without patients, there is no trial. If the overall target sample size is not achieved, the study can be "underpowered", which may potentially jeopardize the validity of the results (Gardner et al., 2016) .
In addition to a clinical trial site with facilities, qualified principal investigators, proper study protocols, and recruitment strategies, the last requirement is to fill the crucial role of study coordinator. Often, registered nurses are assigned this role in randomized clinical trials (Mueller, 2001) . Study coordinators serve as clinical interpreters and patient advocates throughout the course of the trial (Sadler et al., 1999) and are well versed in all aspects of the study protocol, initiate the recruitment of patients, and ensure the clinical care of all subjects. They also record important data from the study subjects in case report forms, assist investigators with skin assessment records, monitor and report serious adverse events, process tissue specimens for laboratory testing, conduct the informed consent process, and schedule all patient visits that last several hours (Green, 2011) . Not only do coordinators need to possess clinical skills to take care of study patients including administration of the study drug if needed but they must also have critical thinking skills to manage the complex ethical, regulatory, and scientific nature of the trial (Green, 2011; Hastings et al., 2012) . Study coordinators manage all dimensions of study trials as well as focus on all aspects of patient care. As noted above, without patients, there would be no trial, and likewise, without coordinators, there would be no study patients. They are an invaluable resource to the clinical trial team.
Challenges of the clinical trials design
Randomized, controlled clinical trials are the optimal method to establish the efficacy of a drug compared with a placebo or another drug (Pincus et al., 2015) . However, because of their design, these trials inherently carry some limitations. One important limitation is related to the relatively short time frame, which can limit the ability to address research questions related to the long-term efficacy, safety, and tolerability of a drug (Pincus et al., 2015) .
Another limitation is the potential distortion of the placebo effect. There is a potential to exaggerate or attenuate the placebo effect when a patient is told that they are receiving treatment in a scientific experiment versus the best therapy from his or her doctor (Pincus et al., 2015) .
Additionally, study enrollment criteria typically exclude patients with certain chronic conditions that are common among the target population for the drug under investigation. Therefore, study results may not be representative of all potential patients who will eventually be administered the drug (Fahey, 1998; Pincus et al., 2015) . Recently, there have been efforts to increase the globalization of randomized clinical trials at multicenter sites. This too can present challenges for the validity of results if different regions have varying recruitment and regulatory procedures (Pocock and Gersh, 2014) .
As previously discussed, patient recruitment plays a vital role in a clinical trial; however, this process does not come without challenges. Barriers that are associated with patient recruitment and enrollment include demands of the trial (i.e., time, blood draws, echocardiograms, etc.), uncertainty about the treatment and possible side effects, and concerns about information in the consent paperwork (Ross et al., 1999) . Experienced study personnel can help address the concerns of patients who are interested in enrolling in a trial to allow patients to make an informed decision on the basis of correct information.
Randomized, controlled, double-blinded studies aim to eliminate bias and contribute valid statistical analyses to the study results (Bagatin and Miot, 2013; Schulz et al., 2002) . However, inherent inter-observer differences and subjectivity exists, especially in dermatologic studies of patients with atopic dermatitis and psoriasis (Futamura et al., 2015) . Even if the sponsor defines strict body surface area and physician global assessment values for patient participation, there remains variations between physicians who perform subjective skin assessments (Futamura et al., 2015) . A lack of perfect standardization between assessments is challenging to make effective comparisons between studies that are used to support clinical decisions (Gerbens et al., 2017) .
Another important challenge with the application of clinical trial results to everyday practice is the historical lack of data from women and minorities. Certain diseases such as breast cancer affect women more than men and can present differently between the sexes (Liu and Mager, 2016) . Responses to treatment can also vary among men and women (Pinn, 2003) with evidence that suggests biological differences at the cellular level (Liu and Mager, 2016) . Studies that fail to recognize the pharmacokinetic differences between the sexes neglect an entire population of study subjects. With this knowledge, the FDA and National Institutes of Health have established initiatives to increase the enrollment of women and minorities in clinical trials.
One problem that is frequently noted in clinical literature is the potential for publication bias (Zarbin, 2016) . Selection bias to report only positive results can negatively influence a clinician's decision to treat a patient when only some of the relevant data is disclosed (Alosh et al., 2009) . Kyzas et al. (2007) reviewed 1915 studies on cancer prognostic markers and noted that approximately 98% of published data referred to statistically significant study results. It is important for clinicians to not only be aware of positive results but also of the negative implications of studies to best care for their patients.
The final challenge is the application of the clinical trial results to one's own practice. A clinician needs to carefully assess whether their patient is adequately represented in the study subject population or the results of a study may not be generalizable to that physician's patient population (Zarbin, 2016) . For all patients, an informed and shared decision-making process needs to occur with the severity of their conditions in mind (Fahey, 1998) . The one-size-fits-all approach does not always hold true when applying results of clinical trial studies (Iwashyna and Deane, 2016) . The biological variability between patients despite similar demographics and disease states needs to be taken into consideration (Zarbin, 2016) . Only then can an individualized treatment plan that is unique to each patient be developed.
Conclusion
It is imperative that we continue to engage in quality clinical trials to support advances in science and medicine. As Ellimoottil et al. (2015) state, "clinical trials are at the heart of medical practice" and a properly developed and implemented trial can alter clinical practice for the better. Regulatory agencies hold randomized clinical trials to the highest standards that are rooted in evidence based medicine when looking at safety and efficacy profiles (Pocock and Gersh, 2014) . Trials are complex and factors that increase transparency within the trial such as preregistration of the trial, reporting of all generated data, clear statistical methods, and publication of all results despite the outcomes will pave the way for effective future treatments (Campa et al., 2016) . With the recent encouraging results of multiple clinical trials of patients with psoriasis who show substantial Psoriasis Area and Severity Index score improvements (Kragballe et al., 2014) , trials are important in the field of dermatology and other medical fields to discover more effective treatment options. In addition to clinical improvement, many chronic conditions such as psoriasis are linked to comorbidities including inflammatory bowel and cardiovascular diseases and depression (Prey et al., 2010; Weng et al., 2007) . Therefore, it is imperative to emphasize clinical trials that also measure improvements in patients' quality of life (Charman et al., 2003) . For clinicians and researchers alike, the goal is to improve the health and lives of the patients they treat, and with properly designed clinical trials, this can and will be consistently achieved worldwide.
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